[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE338046T1 - 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität - Google Patents

2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität

Info

Publication number
ATE338046T1
ATE338046T1 AT02756528T AT02756528T ATE338046T1 AT E338046 T1 ATE338046 T1 AT E338046T1 AT 02756528 T AT02756528 T AT 02756528T AT 02756528 T AT02756528 T AT 02756528T AT E338046 T1 ATE338046 T1 AT E338046T1
Authority
AT
Austria
Prior art keywords
diaza
cyclopenta
oxa
aminomethyl
tetrahydro
Prior art date
Application number
AT02756528T
Other languages
English (en)
Inventor
Richard Eric Mewshaw
Rulin Zhao
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE338046T1 publication Critical patent/ATE338046T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02756528T 2001-07-20 2002-07-19 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität ATE338046T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30693101P 2001-07-20 2001-07-20

Publications (1)

Publication Number Publication Date
ATE338046T1 true ATE338046T1 (de) 2006-09-15

Family

ID=23187510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756528T ATE338046T1 (de) 2001-07-20 2002-07-19 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität

Country Status (12)

Country Link
US (1) US6541502B1 (de)
EP (1) EP1421086B1 (de)
JP (1) JP2004537556A (de)
CN (1) CN100369916C (de)
AT (1) ATE338046T1 (de)
BR (1) BR0211207A (de)
CA (1) CA2454543A1 (de)
DE (1) DE60214397T2 (de)
DK (1) DK1421086T3 (de)
ES (1) ES2271314T3 (de)
MX (1) MXPA04000581A (de)
WO (1) WO2003008419A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014030688A1 (ja) * 2012-08-24 2014-02-27 第一三共株式会社 鎖状側鎖を有するクロモン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE4140540A1 (de) 1991-12-09 1993-06-17 Bayer Ag Neue azaheterocyclylmethyl-chromane
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
AR004523A1 (es) 1995-11-06 1998-12-16 American Home Prod 2-(AMINOMETIL)-3,4,7,9-TETRAHIDRO-2H-PIRANO-[2,3e] INDOL-8-ONAS Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5750556A (en) 1996-10-30 1998-05-12 American Home Products Corporation 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano- 2,3-E!indol-8-ones and derivatives
JP2001509814A (ja) 1997-02-18 2001-07-24 アメリカン・ホーム・プロダクツ・コーポレイション ４−アミノアルコキシ−１ｈ−ベンゾイミダゾール誘導体、それらの調製およびそれらのドパミン自己受容体（ｄ▲下２▼）作動薬としての使用

Also Published As

Publication number Publication date
DK1421086T3 (da) 2006-12-11
US6541502B1 (en) 2003-04-01
ES2271314T3 (es) 2007-04-16
DE60214397D1 (en) 2006-10-12
EP1421086B1 (de) 2006-08-30
WO2003008419A1 (en) 2003-01-30
BR0211207A (pt) 2004-07-13
DE60214397T2 (de) 2007-10-11
MXPA04000581A (es) 2004-04-20
CN100369916C (zh) 2008-02-20
CN1555377A (zh) 2004-12-15
CA2454543A1 (en) 2003-01-30
EP1421086A1 (de) 2004-05-26
JP2004537556A (ja) 2004-12-16

Similar Documents

Publication Publication Date Title
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DK1558579T3 (da) N-alkyl-4-methylenamino-3-hydroxy-2-pyridoner som antimikrobialer
ATE302775T1 (de) Carbolinderivate
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
DK1499577T3 (da) 2-(2,6-dichlorphenyl)-diarylimidazoler
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE346067T1 (de) Carbolinderivate
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
BRPI0409276A (pt) derivados de piperazina inibidores de renina
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
DE60112960D1 (de) Kondensierte pyridoindolderivate
NO20052908L (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
SE0200198D0 (sv) New use
ATE338046T1 (de) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
DK1409490T3 (da) 2-(Aminomethyl)tetrahydro-9-oxa-1,3-diazacyclopenta[a]-naphthalenylderivater med antipsykotisk virkning
HRP20030653B1 (en) Novel benzoylguanidine salt
PA8558901A1 (es) Nuevos compuestos hexaciclicos
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
DK1358182T3 (da) Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties